© Reuters. FILE PHOTO: General view outside GlaxoSmithKline (GSK) headquarters in Brentford, London, Britain, May 4, 2020. REUTERS/Matthew Childs
LONDON (Reuters) -Consumer goods giant Unilever (NYSE:) said it had approached Glaxosmithkline (LON:) about buying the pharmaceutical group’s consumer goods arm after a newspaper reported that a 50 billion pound ($68.4 billion) offer it made had been rebuffed.
“GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio,” Unilever said in a statement on Saturday.
“There can be no certainty that any agreement will be reached.”
GSK did not immediately respond to a request for comment.
Earlier, Britain’s Sunday Times said the Unilever bid for the business was worth roughly 50 billion pounds, and had been rejected as too low by GSK and Pfizer (NYSE:), which owns a minority stake in the division.
The approach by Unilever, which owns brands such as Dove soap and Marmite, for Glaxo’s portfolio of household brands including Panadol painkillers and Sensodyne toothpaste was understood to have been unsolicited, it added.
Unilever’s bid did not include any takeover premium or recognition of synergies, the newspaper said. It was not clear whether Unilever would make a higher offer, it added.
($1 = 0.7314 pounds)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.